Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies [0.03%]
光动力凝胶炸弹可提高肿瘤渗透性及下游联合治疗效果
Xiaole Bai,Fanliang Meng,Xuejiao Wang et al.
Xiaole Bai et al.
Nanoparticle-based drug delivery system remains a significant challenge in the current treatment of solid tumors, primarily due to their limited penetration capabilities. Herein, we successfully engineer photodynamic gel-bombs (DCM@OPR) cap...
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results [0.03%]
单核细胞系肿瘤浸润预测晚期治疗前软组织肉瘤的免疫放射治疗反应：二期试验结果
Antonin Levy,Daphné Morel,Matthieu Texier et al.
Antonin Levy et al.
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable biomarkers...
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics [0.03%]
系统性红斑狼疮：发病机理、诊断、预防和治疗的最新见解
Xiaofeng Dai,Yuting Fan,Xing Zhao
Xiaofeng Dai
Systemic lupus erythematosus (SLE) is a chronic inflammatory illness with heterogeneous clinical manifestations covering multiple organs. Diversified types of medications have been shown effective for alleviating SLE syndromes, ranging from...
Targeting tumor-intrinsic S100 calcium-binding protein A1 augments antitumor immunity and potentiates immunotherapy efficacy [0.03%]
靶向肿瘤内在的S100钙结合蛋白A1可增强抗肿瘤免疫并提高免疫治疗疗效
Yufeng Guo,Rui Wan,Jianchun Duan et al.
Yufeng Guo et al.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, but the therapeutic response is highly heterogeneous, which highlights the necessity for developing predictive biomarkers and overcoming ICB resistance. Cancer cell-intri...
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial [0.03%]
抗PD-1抗体卡瑞利珠单抗联合阿帕替尼和SOX作为AFP阳性胃或胃食管结合部腺癌患者一线治疗（CAP 06）：一项多中心、单臂、二期试验
Yakun Wang,Jialin Lu,Xiaoyi Chong et al.
Yakun Wang et al.
Alpha-fetoprotein-producing gastric or gastro-esophageal junction (AFP-G/GEJ) cancer, a rare gastric cancer subtype, exhibits increased angiogenesis and more immunosuppression than non-AFP-G/GEJ cancer. The potential benefits of anti-angiog...
Tina Kos,Dieter Saur
Tina Kos
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer [0.03%]
增强子转录谱分析揭示了前列腺癌中由增强子RNA驱动的铁死亡及新的治疗机会
Sheng Ma,Zixian Wang,Zezhong Xiong et al.
Sheng Ma et al.
Enhancer RNAs (eRNAs), a subclass of non-coding RNAs transcribed from enhancer regions, have emerged as critical regulators of gene expression; however, their functional roles in prostate cancer remain largely unexplored. In this study, we ...
Advances in the structures, mechanisms and targeting of molecular chaperones [0.03%]
分子伴侣的结构、机制及靶点研究进展
Jinying Gu,Yanyi He,Chenxi He et al.
Jinying Gu et al.
Molecular chaperones, a class of complex client regulatory systems, play significant roles in the prevention of protein misfolding and abnormal aggregation, the modulation of protein homeostasis, and the protection of cells from damage unde...
Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study [0.03%]
沙利度胺为基础的治疗方案在大颗粒淋巴细胞白血病中展现出良好的疗效：多中心Ⅱ期临床试验
Ying Yu,Yuxi Li,Rui Cui et al.
Ying Yu et al.
Large granular lymphocytic leukemia (LGLL) is characterized by the clonal proliferation of cytotoxic T lymphocytes or NK cells. Standard first-line immunosuppressive treatments have limitations, achieving complete remission (CR) rates of up...
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances [0.03%]
神经退行性疾病抗衰老策略：从机制到临床进展
Qiu Jiang,Jie Liu,Shan Huang et al.
Qiu Jiang et al.
In the context of global ageing, the prevalence of neurodegenerative diseases and dementia, such as Alzheimer's disease (AD), is increasing. However, the current symptomatic and disease-modifying therapies have achieved limited benefits for...